Investor Relations (IR) Questions: Arqule Inc ARQL
Click here to return to the biotech IRQ Index
Answers received: February 2013
1) When is the last time ARQL raised cash through an offering (diluted)? In April 2012, ArQule completed an offering of 8.2 million shares, raising approximately $56 million in net proceeds.
2) How much cash (not cash equivalents) does ARQL have? ArQule has guided to ending 2012 with between $127 and $130 million in cash and marketable securities. At the end of the third quarter of 2012, the Company had a total of approximately $140 million in cash, equivalents and marketable securities, of which approximately $83 million is broken out into cash, equivalents and marketable securities – short term and approximately $57 million is broken out into Marketable securities – long term .
3) What and approximately when is the next known catalyst? The next potential catalysts include complete/final data read-outs and presentations from lung cancer and colorectal cancer trials expected to begin in mid-2013 and lasting through early 2014.
4) What is ARQL's quarterly cash burn?
ArQule does not provide quarterly cash burn guidance. For 2012, the Company has guided to a net use of cash ranging between $35 and $38 million.
5) Does ARQL have an existing line of credit and if so how much can they draw against it? No
1) When is the last time ARQL raised cash through an offering (diluted)? In April 2012, ArQule completed an offering of 8.2 million shares, raising approximately $56 million in net proceeds.
2) How much cash (not cash equivalents) does ARQL have? ArQule has guided to ending 2012 with between $127 and $130 million in cash and marketable securities. At the end of the third quarter of 2012, the Company had a total of approximately $140 million in cash, equivalents and marketable securities, of which approximately $83 million is broken out into cash, equivalents and marketable securities – short term and approximately $57 million is broken out into Marketable securities – long term .
3) What and approximately when is the next known catalyst? The next potential catalysts include complete/final data read-outs and presentations from lung cancer and colorectal cancer trials expected to begin in mid-2013 and lasting through early 2014.
4) What is ARQL's quarterly cash burn?
ArQule does not provide quarterly cash burn guidance. For 2012, the Company has guided to a net use of cash ranging between $35 and $38 million.
5) Does ARQL have an existing line of credit and if so how much can they draw against it? No